Physician profile
Faria Khan
NPI 1548212087
$7,245.75
in general payments reported to CMS, 2019-2025
31 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $647 · 2021: $888 · 2022: $1,458 · 2023: $1,197 · 2024: $889 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.86 |
| Education | $203.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,229.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,022.76 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $700.13 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $605.83 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $463.83 | 2019-2023 | Airduo Digihaler |
| Takeda Pharmaceuticals U.S.A., INC. | $429.03 | 2021-2025 | Cuvitru, Takhzyro |
| Novartis Pharmaceuticals Corporation | $386.02 | 2019-2025 | |
| Csl Behring | $324.31 | 2019-2025 | Haegarda, Andembry |
| Amgen INC. | $285.50 | 2021-2025 | Tezspire |
| Optinose US, INC. | $272.51 | 2019-2025 | |
| Pfizer INC. | $236.92 | 2020-2025 | |
| Grifols USA, LLC | $168.05 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Ars Pharmaceuticals Operations, INC. | $142.80 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $135.74 | 2021-2022 | |
| Alk-Abello, INC | $116.98 | 2019-2023 | Grastek, Ragwitek, Odactra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.09 | 2021-2022 | |
| Pharming Healthcare, INC. | $83.98 | 2022-2023 | Ruconest |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Octapharma USA, INC. | $76.79 | 2020 | |
| Covis Pharma Gmbh | $66.54 | 2020-2022 | |
| Incyte Corporation | $46.33 | 2021-2022 | |
| Kaleo, INC. | $45.49 | 2019-2021 | |
| Abbvie INC. | $43.09 | 2022-2024 | |
| Intersect Ent, INC. | $39.76 | 2020 | |
| Aimmune Therapeutics, INC. | $26.45 | 2022 | |
| Adma Biomanufacturing LLC | $26.38 | 2021 | |
| Shire North American Group INC | $20.48 | 2019 | |
| Merck Sharp & Dohme LLC | $20.47 | 2023 | |
| Blueprint Medicines Corporation | $19.15 | 2023 | Ayvakit |
| Mylan Specialty L.P. | $16.30 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faria Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.